Serum CA724 has no diagnostic value for gastrointestinal tumors

Abstract

Objective This study aimed to explore the predictive values of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199, CA125 and CA724 in the diagnosis of gastrointestinal tumors. Methods Among patients treated for gastrointestinal tumors at the First Affiliated Hospital of Wannan Medical College between December 2020 and March 2022, 572 patients were reviewed as the tumor group, and 700 healthy subjects from the physical examination center of the same hospital were reviewed as the control group. We evaluated the correlation between serum CEA, CA199, CA125, CA724 levels and pathological features in 572 patients with gastrointestinal tumors.The levels of serum CEA, CA199, CA125 and CA724 were compared between the two groups, and the area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the diagnostic efficacy of these markers alone and in combination. Results Serum CEA level was correlated with tumor stage and metastasis, and CA199 was correlated with tumor stage, lymph node involvement and metastasis. CA125 and CA724 have no correlation with tumor pathological features. The levels of serum CEA, CA199 and CA125 were significantly increased in the tumor group compared with the control group, while serum CA724 levels did not significantly differ between groups (p > 0.05). In addition, in patients with gastric cancer (GC), esophageal cancer (EC), pancreatic cancer (PC), gallbladder cancer (GBC) or colorectal cancer (CRC), the serum CEA, CA199 and CA125 levels were significantly higher than those in the control group (p < 0.05). However, serum CA724 levels were increased only in CRC patients (p < 0.05). ROC curve evaluation results showed that while CA199, CA125 and CA724 alone had poor diagnostic efficacy in the tumor group, CEA was better. Specifically, CEA had better diagnostic efficacy in GC, PC, GBC and CRC; additionally, CA199 and CA125 had better diagnostic efficacy in PC. However, CA724 showed no diagnostic value in the tumor group and the single gastrointestinal tumor group. For diagnosis with multiple-marker combinations, CEA + CA199 + CA125 had the best diagnostic performance (AUC = 0.776, AUC = 0.650, AUC = 0.896, AUC = 0.840, AUC = 0.793) in the GC, EC, PC, GBC and CRC groups, and the sensitivity of multiple-marker combined detection was better than that of single-marker detection. Conclusions Serum CA724 has no diagnostic value for gastrointestinal tumors, and it cannot evaluate the pathological status of tumors. Serum CEA has excellent diagnostic efficacy in GC, PC, GBC and CRC, and its expression level is related to tumor stage and metastasis. Additionally, CA199 and CA125 have good diagnostic efficacy in PC. Among them, CA199 level was related to tumor stage, lymph node involvement and metastasis, and CA125 level was not related to pathological status. In addition, the multiple-marker combination CEA + CA199 + CA125 has the best diagnostic efficacy in GC, EC, PC, GBC and CRC.

Hsa_circ_0124554 may serve as a biomarker for the diagnosis of colorectal cancer: An observational study

“…According to the findings in Figure 3C, hsa_circ_0124554 may be more useful than CA19-9 in the diagnosis of patients with suspected CRC. Studies have reported that the AUC of CEA in the diagnosis of CRC ranged from 0.709 to 0.739, [25][26][27] but our data showed that the AUC of CEA was 0.831, which may be related to the insufficient sample size in our study. In addition to evaluating the performance of each single marker in detection, we also combined 2 or 3 tumor markers to find the optimal diagnostic combination.…”

Combined Efficacy of Nimotuzumab and Gemcitabine on the Treatment of Advanced Pancreatic cancer

“…Its level is related to tumor size, staging, and metastasis, and it is a relatively new tumor marker in the detection of gastrointestinal and ovarian cancer. 24 Wu noted that pancreatic cancer patients showed a significant upward trend in serum CEA, CA19-9, and CA72-4 levels, with high predictive value for the prognosis of pancreatic cancer patients. 25 Hu suggested that chemotherapy effectively reduced the levels of serum CEA, CA19-9, and CA72-4 in patients with pancreatic cancer and improved their clinical symptoms.…”

Clinical diagnostic value of tRF-24-6VR8K09LE9 and its identification as a novel tumor suppressor in gastric cancer

“…The main cause of malignant changes in GC is metastasis [20]. Traditional markers CEA, CA199 and CA724 are currently used as the main serum markers for GC screening in the clinic, however, due to the limitation of speci city and sensitivity in the early stage of GC, most of these serum markers are relatively limited in the detection of GC [21,22], so it is crucial to nd new serum markers for the clinic that can dynamically monitor the development of GC. For a long time, scientists have been trying to nd suitable markers for GC, and many potential molecules have been identi ed.…”